Mumbai, September 22 (Udaipur Kiran News): Shares of Zydus Lifesciences Ltd edged higher on the BSE after the company received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its oncology injectable facility in Ahmedabad. The stock was trading at ₹1,040.65, up ₹3.65 or 0.35% from the previous close of ₹1,037.00.
The scrip opened at ₹1,039.75 and touched an intraday high of ₹1,042.00 and a low of ₹1,033.75. A total of 4,804 shares were traded during the session. On a weekly basis, the stock has traded between ₹1,059.00 and ₹1,025.30. Zydus Lifesciences’ market capitalisation currently stands at ₹1,04,281.06 crore.
The oncology facility, located at SEZ-1, Ahmedabad, underwent a GMP follow-up inspection from June 9 to June 18, 2025. The EIR classified the facility as Voluntary Action Indicated (VAI), revising its earlier status of Official Action Indicated (OAI) issued in June 2024.
Zydus Lifesciences, formerly known as Cadila Healthcare, is an integrated pharmaceutical company engaged in research, development, manufacturing, marketing, and distribution of a wide range of pharmaceutical products.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
